Cytomegalovirus gastritis in a patient with severe acute respiratory syndrome coronavirus 2 infection: A case report and literature review

Taherifard, Ehsan; Mortazavi, Roozbeh; Mokhtari, Maral; Taherifard, Ali; Salmi, Sima Kiani; Taherifard, Erfan

doi:10.1016/j.rmcr.2022.101644

Cited by 5 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results from a large Italian observational study of COVID-19 patients with moderate to severe acute respiratory distress syndrome [ 32 ] have shown cytomegalovirus (CMV) viraemia/reactivation in 20.4% of patients studied ( Table 2 ). There have been several reports describing CMV reactivation with gastrointestinal tract involvement [ 33 ]. It has been suggested by Alanio et al [ 34 ] that latent CMV infection is associated with an increased risk of COVID-19-related hospitalisation.…”

Section: Covid-19 and Human Herpesviruses Reactivationsmentioning

confidence: 99%

COVID-19, SARS-CoV-2 Vaccination, and Human Herpesviruses Infections

Maple

2023

Vaccines

View full text Add to dashboard Cite

There are several human herpesviruses. A common characteristic of infection by these viruses is latency, by which the virus assumes a non-replicative state, subverting the attentions of the host’s immune response. In immunocompetent hosts, herpesviruses are immunologically controlled, although periodic virus shedding can occur. In situations where immunological control is lost, herpesviruses can reactivate and produce clinically apparent disease. It is now becoming apparent that COVID-19 or exposure to COVID-19 vaccines can exert several effects on the immune system. The pandemic of COVID-19 shows no sign of abating, with new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants continuing to evolve. Several COVID-19 vaccines have been developed, and much of the world’s population has either experienced COVID-19 or been vaccinated against it. There are an increasing number of reports of associations between herpesvirus infections or reactivations and COVID-19 or COVID-19 vaccination. For instance, a positive cytomegalovirus serostatus may indicate a greater likelihood of severe COVID-19, and herpes simplex virus reactivation may be linked to increased mortality. Epstein–Barr virus reactivation appears to be associated with post-acute sequelae of COVID-19. Finally, herpes zoster has been reported to be associated with COVID-19 vaccination. This brief narrative review will provide several insights into associations between herpesvirus infections or reactivations and COVID-19 or SARS-CoV-2 vaccination.

show abstract

Section: Covid-19 and Human Herpesviruses Reactivationsmentioning

confidence: 99%

COVID-19, SARS-CoV-2 Vaccination, and Human Herpesviruses Infections

Maple

2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…COVID‐19 patients are likely to experience an augmented susceptibility to infection, potentially attributable to a combination effect of virus‐induced and drug‐induced immunosuppression 16 . The development of cytomegalovirus (CMV) disease after recovery from the SARS‐CoV‐2 infection has been reported 17–22 . However, there is no large and comprehensive study to investigate the CMV disease after the acute COVID‐19 episode.…”

Section: Introductionmentioning

confidence: 99%

“…However, there is no large and comprehensive study to investigate the CMV disease after the acute COVID‐19 episode. Additionally, the relationship between subsequent CMV disease and COVID‐19 remains unclear because of limited evidence based on mostly case reports 17–22 . Therefore, the objective of this study was to assess the incidence of CMV disease among individuals who have survived COVID‐19, utilizing real‐world data for analysis.…”

Section: Introductionmentioning

confidence: 99%

“…16 The development of cytomegalovirus (CMV) disease after recovery from the SARS-CoV-2 infection has been reported. [17][18][19][20][21][22] However, there is no large and comprehensive study to investigate the CMV disease after the acute COVID-19 episode. Additionally, the relationship between subsequent CMV disease and COVID-19 remains unclear because of limited evidence based on mostly case reports.…”

Section: Introductionmentioning

confidence: 99%

“…Additionally, the relationship between subsequent CMV disease and COVID-19 remains unclear because of limited evidence based on mostly case reports. [17][18][19][20][21][22] Therefore, the objective of this study was to assess the incidence of CMV disease among individuals who have survived COVID-19, utilizing real-world data for analysis. 23,24 The study protocol was approved by the Institutional Review Board of the Chi Mei Medical Center (no.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Risk of cytomegalovirus diseases among coronavirus disease survivors: A retrospective cohort study

Zhang,

Tsai,

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

This study was aimed at investigating the risk of cytomegalovirus (CMV) disease among coronavirus disease 2019 (COVID‐19) survivors. In this retrospective cohort study, we used the TriNetX research network to identify adults with and without COVID‐19 between January 1, 2022 and December 31, 2022. Propensity score matching was used to match the patients with and without COVID‐19. The primary outcome was the risk of CMV disease during the 90‐day follow‐up period. Two matched cohorts comprising 2 501 634 patients with balanced baseline characteristics were created using propensity score matching. During the follow‐up period, patients with COVID‐19 had a higher risk of CMV disease than those without COVID‐19 (hazard ratio [HR], 2.55; 95% confidence interval: 2.01–3.23). The higher risk of CMV disease in the COVID‐19 cohort compared with that of the non‐COVID‐19 cohort remained unchanged in the subgroup analyses by sex (men: HR, 1.85 [1.38–2.47]; women: HR, 2.31 [1.63–3.27]), age (18–64 years: HR, 2.21 [1.71–2.85]; ≥65 years: HR, 1.97 [1.20–3.25]), obesity (HR, 1.54 [1.04–2.30]), diabetes mellitus (HR, 1.50 [1.08–2.08]), cancer (HR, 3.10 [1.95–4.92]), glucocorticoid use (HR, 3.14 [2.45–4.02]), transplantation (HR, 1.38 [1.08–1.77]), and unvaccinated status (HR, 2.37 [1.82–3.08]). In conclusion, COVID‐19 can increase the risk of CMV disease. Clinicians should be aware of the risk of CMV disease in patients with COVID‐19.

show abstract

Methylprednisolone/tocilizumab

2022

Reactions Weekly

View full text Add to dashboard Cite

Cytomegalovirus gastritis in a patient with severe acute respiratory syndrome coronavirus 2 infection: A case report and literature review

Cited by 5 publications

References 23 publications

COVID-19, SARS-CoV-2 Vaccination, and Human Herpesviruses Infections

COVID-19, SARS-CoV-2 Vaccination, and Human Herpesviruses Infections

Risk of cytomegalovirus diseases among coronavirus disease survivors: A retrospective cohort study

Methylprednisolone/tocilizumab

Contact Info

Product

Resources

About